Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Common Equity: 2015-2024

Historic Common Equity for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to $288.1 million.

  • Syndax Pharmaceuticals' Common Equity fell 68.50% to $115.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $115.4 million, marking a year-over-year decrease of 68.50%. This contributed to the annual value of $288.1 million for FY2024, which is 48.01% down from last year.
  • Per Syndax Pharmaceuticals' latest filing, its Common Equity stood at $288.1 million for FY2024, which was down 48.01% from $554.2 million recorded in FY2023.
  • Syndax Pharmaceuticals' Common Equity's 5-year high stood at $554.2 million during FY2023, with a 5-year trough of $252.2 million in FY2020.
  • Its 3-year average for Common Equity is $436.6 million, with a median of $467.4 million in 2022.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 698.06% in 2020, then crashed by 48.01% in 2024.
  • Yearly analysis of 5 years shows Syndax Pharmaceuticals' Common Equity stood at $252.2 million in 2020, then surged by 61.93% to $408.4 million in 2021, then increased by 14.47% to $467.4 million in 2022, then rose by 18.56% to $554.2 million in 2023, then slumped by 48.01% to $288.1 million in 2024.